Depression is a highly prevalent psychiatric condition, with over 300 million sufferers, and is an important comorbidity for other conditions, like cardiovascular disorders or diabetes. Therapy is largely based on psychotherapy and/or pharmacological intervention, particularly aimed at altering neurotransmitter levels in the central nervous system, but inadequate response to treatment remains a significant clinical problem. Herein, evidence supporting a molecular link between inflammation and depression will be discussed, particularly the increased prevalence of depression in chronic inflammatory diseases and the evidence on the use of anti-inflammatory drugs to treat depression. Moreover, the potential for the levels of peripheral inflammatory molecules to act as depression biomarkers, in the diagnosis and monitoring of depression will be examined, considering clinical- and animal model-based evidence.
CITATION STYLE
Brás, J. P., Pinto, S., Almeida, M. I., Prata, J., von Doellinger, O., Coelho, R., … Santos, S. G. (2019). Peripheral biomarkers of inflammation in depression: Evidence from animal models and clinical studies. In Methods in Molecular Biology (Vol. 2011, pp. 467–492). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9554-7_28
Mendeley helps you to discover research relevant for your work.